A real world major data study for Apatinib in the treatment of advanced gastric cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800017789

Enrollment

Unknown

Registered

2018-08-14

Start date

2018-08-15

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced gastric cancer

Interventions

Case series:Apatinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years old; 2. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction); 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with contraindication; 3. patients who physicians suggest not be included.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Secondary

Measure	Time frame
OS;1 year OS rate;2 year OS rate;ORR;DCR;Safety;	—

Countries

China

Contacts

Public ContactXiangdong Cheng, Jie'er Ying

Zhejiang Provincial Hospital of TCM, Zhejiang Cancer Hospital

jieerying@aliyun.com+86 13858195803

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026